The Psychopharmacologic Drugs Advisory Committee of the FDA voted 12-to-5 in favor of approving Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine, the first long-acting, subdermal buprenorphine implant for the maintenance...
Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has released preliminary unaudited revenue for the fourth quarter of 2015 of approximately $20-million, reflecting increases of about 54% from $13-million in the 2014 fourth...
Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has announced its anticipated clinical milestones for 2016. “We are very encouraged by the clinical and preclinical data from each of our drugs to date, which indicate their...
In a letter to shareholders, Cameron Groome, CEO of Avivagen (TSX-V:VIV), provided and update about the company and its business plans. Mr. Groome said Avivagen continues the process of commercializing its non...
BioLight Israeli Life Sciences Investments (OTCQX: BLGTY; TASE: BOLT) has completed a second successful U.S. clinical study to assess the effectiveness of its TeaRx multi-assay test in evaluating tears’ components of...
In a letter to shareholders, Nadav Kidron, CEO of Oramed Pharmaceuticals (NASDAQ:ORMP), detailed the company’s recent achievements and future milestones. “2015 was a very significant year for us at Oramed, setting the...
Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has submitted its Phase 3 clinical study protocol to the Institutional Review Board of Barzilai Medical Center in Israel and will file similar submissions in several...
Fibrocell Science (NASDAQ:FCSC) and Intrexon (NYSE:XON) agreed to an exclusive channel collaboration for the development of genetically-modified fibroblasts to treat chronic inflammatory and degenerative diseases of the...
The CBS affiliate in Philadelphia has produced a news segment about Titan Pharmaceutical’s (NASDAQ:TTNP) Probuphine implant for the maintenance treatment of opioid addiction. According to the CBS segment, experts say...
The Canadian Medical Devices Bureau has approved BioLight Life Sciences Investments’ (OTCQX:BLGTY; TASE:BOLT) IOPtiMate system for the treatment of glaucoma, allowing the company to commercialize the surgical system in...
The Japan Patent Office has granted Can-Fite BioPharma (NYSE MKT:CANF) (TASE:CFBI) a patent for its lead drug candidate, CF101, for the reduction of intraocular pressure (IOP). CF101 is an A3 adenosine receptor (A3AR)...
Closely-held Soricimed Biopharma has reached its target enrollment and treatment duration in a Phase 1 trial to evaluate the safety and tolerability of SOR-C13 in patients with solid tumor cancers who have failed other...
Closely-held BioSight of Israel reported positive interim results in an abstract at the ASH meeting last week from a Phase 1/2a clinical study of Astarabine in leukemia patients. The aim of the study was to evaluate the...
The FDA’s Psychopharmacologic Drugs Advisory Committee has scheduled a meeting on Jan. 12 to review the NDA for Titan Pharmaceuticals’ (NASDAQ: TTNP) Probuphine for the maintenance treatment of opioid addiction. The FDA...
Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) subsidiary, OphthaliX (OTCQB:OPLI), has completed enrollment of 88 patients in its Phase 2 trial of CF101, an oral treatment for glaucoma. The trial is being conducted in...
Closely-held Ciclofilin Pharmaceuticals has assembled a world-class team of scientists and clinicians for its scientific advisory board (SAB) to guide the company through its drug development program for its lead drug...
BioLight Life Sciences Investments’ (OTCQX:BLGTY; TASE:BOLT) cancer diagnostics subsidiary, Micromedic Technologies (TASE:MCTC), has entered into a collaboration agreement with Axella Research to advance the clinical...
Oramed Pharmaceuticals (NASDAQ:ORMP) has signed definitive licensing and investment agreements valued at up to $50-million with Hefei Tianhui Incubator of Technologies (HTIT) for exclusive rights to market Oramed’s oral...
BioLight Life Sciences Investments (OTCQX:BLGTY; TASE:BOLT) and two Asia-based venture capital firms have entered into a joint financing agreement for a direct equity investment in BioLight’s IOPtima subsidiary via a...
Kitov Pharmaceuticals Holdings (NASDAQ:KTOV) has priced an initial public offering of 3,158,900 American Depository Shares (ADS) and warrants to purchase up to 3,158,900 ADS for gross proceeds expected to be...
Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) drug candidate, CF102, which is currently in Phase 2 trials for hepatocellular carcinoma (HCC), the most common form of liver cancer, will be expanded into the treatment...
Closely-held B-TEMIA has initiated a multi-center pivotal trial aimed at demonstrating the superior clinical benefits and safety for home use of its powered-assistive Dermoskeleton technology, called Keeogo, for...